IMCR
Immunocore Holdings plc
$31.95
-1.13 (-3.42%)
At close · Jul 10
Market Cap
$1.63B
Shares
50,865,574
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$400.02M
+29%
FY2025
Net Income
-$35.51M
+30.5%
FY2025
Gross Margin
98.73%
-0.4pp
FY2025
Operating Margin
-11.34%
+11.4pp
FY2025
Diluted EPS
-$0.71
+30.4%
FY2025
Operating Cash Flow
-$10.71M
-141.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $412.81M | $400.02M | $310.2M | $249.43M | — | — | |
| $4.69M | $5.09M | $2.73M | $1.04M | — | — | |
| $408.12M | $394.93M | $307.47M | $248.39M | — | — | |
| — | 98.73% | 99.12% | 99.58% | — | — | |
| $279.51M | $274.87M | $222.15M | $163.55M | — | — | |
| $163.07M | $165.41M | $155.78M | $144.5M | — | — | |
| — | $3.1M | $4.2M | $4.1M | — | — | |
| -$34.46M | -$45.35M | -$70.46M | -$59.65M | — | — | |
| — | -11.34% | -22.71% | -23.91% | — | — | |
| — | -$42.25M | -$66.26M | -$55.55M | — | — | |
| $12.19M | $12.17M | $18.84M | $5.15M | — | — | |
| $15.72M | $16.48M | $25.62M | $17.99M | — | — | |
| $16.04M | $19.73M | $14.2M | -$897K | — | — | |
| -$11.91M | -$19.1M | -$52.94M | -$60.89M | — | — | |
| $15.65M | $16.41M | -$1.85M | -$5.6M | — | — | |
| -$27.57M | -$35.51M | -$51.09M | -$55.29M | -$52.54M | -$180.03M | |
| — | -8.88% | -16.47% | -22.17% | — | — | |
| -$29.85M | -$29.84M | -$48.59M | -$36.88M | — | — | |
| USD/shares | — | -$0.71 | -$1.02 | -$1.13 | — | — |
| USD/shares | — | -$0.71 | -$1.02 | -$1.13 | — | — |
| shares | — | 50.35M | 49.99M | 48.89M | — | — |
| shares | — | 50.35M | 49.99M | 48.89M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.70×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment | $400,016,000 | $310,202,000 | $249,428,000 | $174,361,000 |
By Geography (USD)
| Component | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| United States | $169,791,000 | $96,893,000 | $0 |
| Europe | $67,628,000 | $42,745,000 | $4,078,000 |
| Rest of World | $1,316,000 | $1,049,000 | $0 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Sale of Therapies | $400,016,000 | $309,989,000 | $238,735,000 | $140,687,000 | — |
| Collaboration Revenue | $0 | $213,000 | $10,693,000 | $33,674,000 | — |
| Pre Product | — | — | — | — | $4,078,000 |
| Product | — | — | — | — | $0 |